WO2022094640A1 - Préparation contenant un constituant aldéhyde pour le traitement de l'onychomycose - Google Patents

Préparation contenant un constituant aldéhyde pour le traitement de l'onychomycose Download PDF

Info

Publication number
WO2022094640A1
WO2022094640A1 PCT/AT2021/060404 AT2021060404W WO2022094640A1 WO 2022094640 A1 WO2022094640 A1 WO 2022094640A1 AT 2021060404 W AT2021060404 W AT 2021060404W WO 2022094640 A1 WO2022094640 A1 WO 2022094640A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
aqueous composition
use according
nail
volatile
Prior art date
Application number
PCT/AT2021/060404
Other languages
German (de)
English (en)
Inventor
Thomas Bechtold
Martin RINDERER
Oezkan GUELBAHAR
Peter LUDER
Original Assignee
Universität Innsbruck
Liemed Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Innsbruck, Liemed Ag filed Critical Universität Innsbruck
Publication of WO2022094640A1 publication Critical patent/WO2022094640A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Definitions

  • the invention relates to a preparation for use in the treatment of onychomycosis.
  • Infection weakens and damages the nail plate, resulting in visual and structural changes. Yellowish, white changes in the nail are observed, which can extend to the nail bed.
  • the nail fungus infection is painless, so in many cases, after several unsuccessful attempts at treatment, the infection is accepted as chronic.
  • the changed appearance of the toenails leads to personal restrictions for many people, e.g. in the choice of footwear, since the affected toes do not like to be shown visibly.
  • impermeable gloves e.g. clean room staff, people in medical professions, etc.
  • Treatment of nail fungus infestation depends on the severity of the infestation (intensity of infection, number of nails affected) and can be carried out locally by applying appropriate active substances, by completely removing the nail or systemically by administering appropriate active substances, e.g. in oral form.
  • Shift in the biological living conditions in the area of the affected nail areas includes methods using organic acids (e.g. salicylic acid according to US 2011/0160166 A1) achieve a local shift in the pH range and thus change the propagation conditions for the nail fungus so much that further growth is prevented or at least slowed down (US 2014/0142177 A1, WO 2010/019777 A1 ).
  • organic acids e.g. salicylic acid according to US 2011/0160166 A1
  • fungicidally active substances include substances that have a high toxicity for fungi (bifonazole, clotrimazole, ciclopirox, amorolfm or metal pyrithione according to US 2009/0298805 A1 or formaldehyde according to FR 2 805 745 B1) and, for example, like nail polish can be applied.
  • Lavender oil Lavender oil, tea tree oil (US 2006/0251593) and plant extracts are proposed in different preparation forms for the treatment of fungal nail infections.
  • Laser treatments Laser light is used to locally remove the affected areas. The affected areas are removed by increasing the temperature.
  • the swelling agents are substances containing mercaptan groups, which are able to soften the nail structure by swelling (US Pat. No. 6,123,690 and US Pat. No. 5,696,164).
  • oral antimycotics such as griseofulvin, itraconazole, terbinafine (WO 2010/010470 A2) or fluconazole are administered over a longer period of time.
  • These treatments require long periods of time because the antifungal agents have to be stored in the nail structure, which can contain the infection.
  • the health side effects of this long-term drug administration are considerable.
  • the high number of nail fungus infections that still exist today in economically highly developed countries confirms the hitherto inadequate suitability and effect of the proposed solutions, which have a large number of disadvantages.
  • fungicidal substances such as bifonazole, clotrimazole, ciclopirox and amorolfm only have a limited effect. This is mainly due to two systematic causes: The substances are high-molecular substances and are insoluble in water. As a result, the preparations are systems with solubilizers or emulsions, which are difficult to penetrate into the branched and deep growth areas in affected nails. A much more critical disadvantage also lies in the increasing resistance of the fungi to known active substances.
  • Formulations which contain the sometimes extremely toxic solid substances such as lead or mercury salts are disadvantageous because of the high toxicity of the substances.
  • lacquer polymers to strengthen the nail structure has been described in the literature (DE 20 2013 009 976 U1). If antifungal substances are incorporated into the lacquer formulation, an antifungal nail lacquer is produced (DE 20 2013 009 988 U1), with the use of formaldehyde being explicitly excluded in the formulation claimed in DE 20 2013 009 988 U1.
  • formaldehyde Due to its high chemical reactivity, formaldehyde has a strong disinfecting effect and is still an important disinfectant in medical cleaning agents today. Chemical resistance of microorganisms to formaldehyde and other aldehydes or aldehyde-releasing substances is not to be expected due to the chemical reactivity and the biocompatibility or the occurrence in the metabolism.
  • Formaldehyde is usually used as an aqueous solution (formalin) or in gaseous form.
  • AT 516 544 B1 describes a preparation for local treatment, which is an aqueous solution containing an aldehyde component, a surfactant and a water-miscible solvent.
  • the special composition ensures deep penetration into the nail and has a particularly good effect against nail fungus.
  • the object is therefore to provide a preparation which is suitable for the local treatment of nail fungus and is easy to handle and which enters the affected nail structure.
  • the pH buffer system thus has a volatile component.
  • the pH of the composition is between 7 and 9 after evaporation of the volatile component.
  • the present invention uses the antimicrobial effect of aldehydes or aldehyde-releasing compounds to combat fungal infestation of the toenails or fingernails. By adding a substance that reduces the surface tension, the penetration depth of an aldehyde-containing aqueous solution into the damaged nail areas is increased to such an extent that the unwanted fungal infestation can be completely eliminated.
  • aldehyde component includes substances that themselves contain aldehyde groups (such as formaldehyde, propionic acid dialdehyde, succinic acid dialdehyde, glutaraldehyde, glyoxal, methylglyoxal) but also chemical compounds that are capable of splitting off aldehydes. These include, for example, acetals such as dimethylformal, 2,5-dimethoxytetrahydrofuran, 1,1,3,3-tetraethoxypropane, hemiacetals and aminals.
  • aldehyde groups such as formaldehyde, propionic acid dialdehyde, succinic acid dialdehyde, glutaraldehyde, glyoxal, methylglyoxal
  • acetals such as dimethylformal, 2,5-dimethoxytetrahydrofuran, 1,1,3,3-tetraethoxypropane, hemiacetals and aminals
  • the aldehyde component is glutaraldehyde.
  • the term surface tension reducing substance includes substances which reduce the surface tension of the composition compared to this composition without the surface tension reducing substance.
  • substances that reduce surface tension are, in particular, surfactants, but additives to solvents can also be used to reduce surface tension.
  • suitable surfactants are the alkyl sulfates, alkyl sulfonates and alkyl ether sulfates or, for example, the alkyl phosphonates and alkyl phosphates.
  • the chemical group of the tenside should be selected in such a way that the function of the tenside is not deactivated by reaction with the aldehyde component.
  • the surfactant is selected from the group consisting of quaternary ammonium salts and is preferably itself a biocidally active substance.
  • Surfactants are particularly preferably selected from the group of quaternary ammonium salts, for example didecyldimethylammonium chloride or benzyl-Cu-Cis-alkyldimethylammonium chloride, which themselves also have an antimicrobial effect.
  • the treatment solution can penetrate sufficiently deep into the very fine growth channels in the affected nail areas. Due to the high penetration depth, a complete treatment of the affected areas is achieved.
  • the high disinfecting effect of the aldehydes also allows treatment and elimination of fungal spores.
  • the reaction of the aldehydes with the nail keratin results in a superficial sealing of the horn structure and a new infestation is made more difficult by the depot effect.
  • a pH buffer system is a mixture of substances whose pH value (concentration of oxonium ions) changes much less when an acid or a base is added than would be the case in an unbuffered system.
  • Buffer solutions contain a mixture of a weak acid and its conjugate or corresponding base (or the respective salt) or a weak base and its conjugate or corresponding acid.
  • the pH buffer system used in the composition according to the invention is a buffer which adjusts the pH to a maximum of pH 6. This makes the composition storage-stable. The composition therefore has a pH of 6 at most.
  • One of the components of the buffering system is a volatile component.
  • the pH rises to 7 to 9 by evaporation of the volatile component of the buffer system, preferably an acid of the buffer system.
  • the volatile component is therefore preferably an acid, particularly preferably an organic acid.
  • this evaporation occurs, for example, following the local application of the composition to the affected nail.
  • the increase in pH at the application site results in the local pH being shifted in the direction of the optimal pH for the application.
  • glutaraldehyde it is known from the literature that an optimum effect of the antimicrobial effect is observed at a pH value of 7.5-8.5.
  • the pH buffering system is to be understood that the pH of the entire composition is in the ideal stabilizing range for the composition, preferably the pH of the composition is at most 6.
  • the pH After evaporation of the volatile component of the pH buffer system, the pH begins to rise and reaches a maximum of 7 to 9.
  • a buffer system with these properties can easily be determined by the person skilled in the art with knowledge of pKa values and the Henderson-Hasselbalch equation.
  • the buffer system comprises acetic acid/acetate.
  • buffer systems with other moderately strong acids and their corresponding moderately strong bases and mixtures thereof are also possible.
  • formic acid, acetic acid, propionic acid can also be used as the acid and the corresponding salts of these acids or mixtures thereof can be used as the base.
  • a volatile, water-miscible solvent is additionally provided.
  • the volatility of the solvent supports and improves the reach of all affected areas, as high concentrations of disinfectant can be generated locally, inside the nail.
  • solvents are acetone, but also alcohols and polyethylene glycols, it being important to ensure that any acetal/hemiacetal compound that may form can decompose reversibly to form the aldehyde components and the inventive effect of the preparation is therefore not lost.
  • the volatile solvent or solvent mixture can also lower the surface tension.
  • a possible reaction of the solvent with the aldehyde components is only permissible if the reaction is reversible and the aldehyde component can be released again by reverse reaction during use, so that the effect according to the invention occurs.
  • alcohols are used which are also used as biocides, for example 1-propanol, 2-propanol or ethanol.
  • the volatile, water-miscible solvent is an alcohol.
  • Alcohols can achieve an increase in local concentration when using an aldehyde component with a higher boiling point, e.g. glutaraldehyde.
  • suitable alcohols are selected, for example, from the group consisting of 1-propanol, 2-propanol, ethanol or mixtures thereof.
  • volatile (be it as a volatile component of the pH buffer system or as a volatile solvent) based on Directive 2004/42 / EC of the European Parliament and of the Council of April 21, 2004 on the limitation of Emissions of volatile organic compounds are understood to mean that the volatile component of the pH buffer system or the volatile solvent is an organic compound that has an initial boiling point of maximum 250 °C at a standard pressure of 1013 mbar having.
  • the vapor pressure of this compound is preferably at least 0.1 mbar at 20° C. (to be calculated, for example, using the Clausius-Clapeyron equation).
  • composition of the preparation is preferably as follows:
  • the individual values refer to the entire composition.
  • the amount of surface tension reducing agent is preferably between 0.05 and 10% by weight.
  • the surface tension reducing agent is a surfactant, the proportion is preferably 0.05 to 5% by weight, more preferably 0.1 to 3% by weight.
  • the pH buffer system is an acetic acid/acetate buffer with 0.02-0.4% by weight acetic acid and 0.03-0.6% by weight acetate salt, preferably sodium acetate.
  • Colorants, dyes or fragrances are particularly suitable as "other substances". However, these must be compatible with the function of the aldehyde component and the surface tension reducing component.
  • natural or nature-identical fragrances such as citronellal, peppermint oil or lavender oil are used, which also have an antimicrobial effect (ideally 0.1 to 5% by weight).
  • the invention relates to a preparation of the aforementioned type as a medicament.
  • the invention relates to a preparation of the aforementioned type for the treatment of onychomycosis (nail fungus).
  • Topical treatment can be done by applying the preparation to a nail.
  • the invention is based on the knowledge of the combination of up to 4 different active substance groups for the treatment of nail fungus:
  • aldehyde components e.g. Glutaraldehyde, methylglyoxal, etc. serves as the primary mechanism.
  • a substance that reduces surface tension (usually a tenside component) is used to ensure good wetting of the nail and lower surface tension, which is compatible with aldehydes.
  • a volatile solvent e.g. isopropanol (which ideally also has an antimicrobial effect) supports the transport of the aldehyde component to the desired location.
  • a pH buffer system which shifts the pH value in the nail to the range of 8 - 9 through evaporation, improves the optimal effect of the aldehyde component, while increased stability is achieved during storage due to the lower pH value, e.g. pH 5 to 6 .
  • fragrances can also be used which themselves have an antimicrobial effect and thus, in addition to the development of a fresh smell, also support the antifungal function themselves through a germ-killing effect.
  • the treatment solution By lowering the surface tension, the treatment solution penetrates very deeply into the dry nail, resulting in a very thorough treatment.
  • the preparation is then allowed to dry.
  • the alcohol component initially has a germicidal effect, after rapid evaporation an increased concentration of antimicrobial aldehyde, surfactant and fragrance remains.
  • the slow evaporation of the volatile organic acid from the buffer leads to a gradual increase in the pH value, and thus to the formation of the optimal effect of the aldehyde component, which can be e.g. glutaraldehyde.
  • a composition according to the invention contains the antimicrobial agents glutaraldehyde and 2-propanol.
  • the buffer system consists of acetic acid and sodium acetate. 1 to 2 drops of the product are applied to the nail affected by the nail fungus and then allowed to air dry. The evaporation of the acetic acid shifts the pH of the solution into the optimal range of action of the glutaraldehyde.
  • the formula has been used on several people with toenail fungus.
  • the treatment was carried out three times during the first week, then 2 to 3 times a week during the following month and then 1 to 2 times a month. After just a few weeks of treatment, healthy nails were growing back in the treated areas.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composition aqueuse contenant un constituant aldéhyde, une substance diminuant la tension superficielle, un système tampon de pH, et un constituant volatil.
PCT/AT2021/060404 2020-11-06 2021-11-04 Préparation contenant un constituant aldéhyde pour le traitement de l'onychomycose WO2022094640A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA50958/2020A AT524378A1 (de) 2020-11-06 2020-11-06 Zubereitung
ATA50958/2020 2020-11-06

Publications (1)

Publication Number Publication Date
WO2022094640A1 true WO2022094640A1 (fr) 2022-05-12

Family

ID=78621561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2021/060404 WO2022094640A1 (fr) 2020-11-06 2021-11-04 Préparation contenant un constituant aldéhyde pour le traitement de l'onychomycose

Country Status (2)

Country Link
AT (1) AT524378A1 (fr)
WO (1) WO2022094640A1 (fr)

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3382151A (en) 1964-01-13 1968-05-07 Mavala Sa Composition for strengthening nails
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US6123690A (en) 1998-03-20 2000-09-26 Maersk Medical A/S Subcutaneous infusion device
FR2805745A1 (fr) 2000-03-01 2001-09-07 Bergerac Nc Compositions pour vernis a ongles antifongiques et antiseptiques
US20060251593A1 (en) 2005-04-07 2006-11-09 Work By Docs, Inc. Colored nail enamel treatment
US20090298805A1 (en) 2008-06-03 2009-12-03 Polson George A Topical pyrithione compositions and methods for treatment of nail fungus
WO2010010470A2 (fr) 2008-07-23 2010-01-28 Tdt, Ltd Procédé d’administration de formulations antifongiques topiques pour le traitement d’infections fongiques
WO2010014070A1 (fr) 2008-07-31 2010-02-04 Medtronic, Inc. Détection d'une aggravation d'insuffisance cardiaque selon des mesures d'impédance
WO2010019777A1 (fr) 2008-08-13 2010-02-18 Dermworx Incorporated Agent anti-infectieux local pour traitement d'infections fongiques de l'ongle
WO2010125398A2 (fr) 2009-05-01 2010-11-04 Insense Limited Traitement d'une infection de surface du corps humain ou animal
US20110160166A1 (en) 2009-12-31 2011-06-30 Karen Hohenstein Therapeutic composition for the treatment and prevention of athlete's foot and fungal infections of the nail and surrounding tissues
WO2011155887A1 (fr) 2010-06-07 2011-12-15 Topical Pharma Ab Kit pour le traitement de l'onychomycose par l'oxyde nitrique
DE202013009976U1 (de) 2013-11-04 2013-12-12 Jerg-Hanns Wohnhas Kosmetischer oder pharmazeutischer Nagellack, Nagellasur, Nagellack-Basis und/ oder Nagelhärter
DE202013009988U1 (de) 2013-11-04 2013-12-12 Jerg-Hanns Wohnhas Biologischer antimykotischer Nagellack, Nagellasur, und/oder Nagelhärter
US20140142177A1 (en) 2009-05-15 2014-05-22 Peter Mladenovich Topical organic acid salt compositions suitable for treating infections
DE102015223901A1 (de) * 2014-12-02 2016-06-02 Universität Innsbruck Zubereitung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP655198A0 (en) * 1998-10-19 1998-11-05 Whiteley Industries Pty Ltd Improved high level disinfectant
RU2710732C2 (ru) * 2014-10-05 2020-01-10 Микробайд Лимитед Композиция для борьбы с насекомыми, содержащая альдегид
WO2019055925A1 (fr) * 2017-09-15 2019-03-21 Gojo Industries, Inc. Composition antimicrobienne

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3382151A (en) 1964-01-13 1968-05-07 Mavala Sa Composition for strengthening nails
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US6123690A (en) 1998-03-20 2000-09-26 Maersk Medical A/S Subcutaneous infusion device
FR2805745A1 (fr) 2000-03-01 2001-09-07 Bergerac Nc Compositions pour vernis a ongles antifongiques et antiseptiques
FR2805745B1 (fr) 2000-03-01 2002-12-13 Bergerac Nc Compositions pour vernis a ongles antifongiques et antiseptiques
US20060251593A1 (en) 2005-04-07 2006-11-09 Work By Docs, Inc. Colored nail enamel treatment
US20090298805A1 (en) 2008-06-03 2009-12-03 Polson George A Topical pyrithione compositions and methods for treatment of nail fungus
WO2010010470A2 (fr) 2008-07-23 2010-01-28 Tdt, Ltd Procédé d’administration de formulations antifongiques topiques pour le traitement d’infections fongiques
WO2010014070A1 (fr) 2008-07-31 2010-02-04 Medtronic, Inc. Détection d'une aggravation d'insuffisance cardiaque selon des mesures d'impédance
WO2010019777A1 (fr) 2008-08-13 2010-02-18 Dermworx Incorporated Agent anti-infectieux local pour traitement d'infections fongiques de l'ongle
WO2010125398A2 (fr) 2009-05-01 2010-11-04 Insense Limited Traitement d'une infection de surface du corps humain ou animal
US20140142177A1 (en) 2009-05-15 2014-05-22 Peter Mladenovich Topical organic acid salt compositions suitable for treating infections
US20110160166A1 (en) 2009-12-31 2011-06-30 Karen Hohenstein Therapeutic composition for the treatment and prevention of athlete's foot and fungal infections of the nail and surrounding tissues
WO2011155887A1 (fr) 2010-06-07 2011-12-15 Topical Pharma Ab Kit pour le traitement de l'onychomycose par l'oxyde nitrique
DE202013009976U1 (de) 2013-11-04 2013-12-12 Jerg-Hanns Wohnhas Kosmetischer oder pharmazeutischer Nagellack, Nagellasur, Nagellack-Basis und/ oder Nagelhärter
DE202013009988U1 (de) 2013-11-04 2013-12-12 Jerg-Hanns Wohnhas Biologischer antimykotischer Nagellack, Nagellasur, und/oder Nagelhärter
DE102015223901A1 (de) * 2014-12-02 2016-06-02 Universität Innsbruck Zubereitung
AT516544B1 (de) 2014-12-02 2017-05-15 Universität Innsbruck Stoffgemisch und Zubereitung

Also Published As

Publication number Publication date
AT524378A1 (de) 2022-05-15

Similar Documents

Publication Publication Date Title
DE19782324B4 (de) Insektizidkombination gegen Läuse von Säugern, insbesondere von Hunden und Katzen
JPWO2007102241A1 (ja) 外用の医薬組成物
EP2190425B1 (fr) Agents fongicides à usage topique pour le traitement des ongles
EP1924144B1 (fr) Produit desinfectant pour blessures et muqueuses
WO2020176697A1 (fr) Compositions repoussant les insectes et leurs procédés de fabrication
EP2196090A1 (fr) Produit de désinfection virucide
EP0552853B1 (fr) Desinfectant et produit conservateur aldéhydique stabilisé
DE4225795C2 (de) Desinfektionsmittel auf Carbonsäurebasis
WO2022094640A1 (fr) Préparation contenant un constituant aldéhyde pour le traitement de l'onychomycose
DE102020204730A1 (de) Hautdesinfektionsmittel
DE4301295C2 (de) Wäßriges Desinfektionsmittelkonzentrat und Desinfektionsmittel auf Aldehyd- und Alkoholbasis und deren Verwendung
AT516544B1 (de) Stoffgemisch und Zubereitung
DE102005006104A1 (de) Verschäumbare alkoholische Mittel mit Desinfektions- und Reinigungswirkung auf (Erd)Alkali- Basis und deren Verwendung
EP0692192A1 (fr) Préparation alcoolique d'agent désinfectant et son utilisant
EP0986301B1 (fr) Insectifuge
EP2410861B1 (fr) Composition répulsive pour application topique sur des êtres vivants
EP1020115B1 (fr) Agent désinfectant et antiseptique à base d'alcools
DE19901526B4 (de) Desinfektionsmittel und Antiseptikum auf der Basis von Alkoholen
DE4004014C2 (de) Verwendung eines Methylcyclosiloxan enthaltenden Mittels zur Desinfektion der Haut
EP1869979B1 (fr) Agent contre les poux de tête
DE4424325C1 (de) Alkoholische Desinfektionsmittel-Zubereitung
AT216678B (de) Verfahren zur Herstellung von fungicid wirksamen Präparaten
DE102020204728A1 (de) Hautdesinfektionsmittel
DE102015105386A1 (de) Stabile Lösungen von Carbonsäuren und Carbonsäuresalzen in wässrigen Alkandiolen und deren Verwendung
EP3133918B1 (fr) Disinfectant pour les mains

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21806945

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21806945

Country of ref document: EP

Kind code of ref document: A1